Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralinepag phase 3 study in recently treated WHO Group 1 pulmonary hypertension
2019-003309-88Phase 3Unknown
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) comparing Ralinepag plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Change from baseline in peak oxygen consumption. Status: unknown.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2019-003309-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003309-88.